TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enzyme Research
Studies from Y. Yuhas and colleagues yield new information about enzyme research
May 19th, 2009
According to a study from Israel, "Rifampin (rifampicin), an important antibiotic agent and a major drug used for the treatment of tuberculosis, exerts immunomodulatory effects. Previous studies have found that rifampin increases inducible nitric oxide (NO) synthase (iNOS) expression and NO production." "The present study investigated the potential mechanism(s) underlying these actions. The incubation of human lung epithelial A549 cells with a cytokine mix (interleukin-1 beta, tumor necrosis factor alpha, and gamma interferon) induced the expression of iNOS mRNA. The addition of rifampin increased the iNOS level by 1.9 +/- 0.3-fold at a dose of 10 mu g/ml (P < 0.01)...
Source: TB & Outbreaks Week (2009-05-19)
|
